Sodium cyanoborohydride (CAS NO : 25895-60-7)

Sodium cyanoborohydride (CAS No: 25895-60-7) serves as a pivotal, highly selective reducing agent in the global pharmaceutical and fine chemical industries, particularly valued for its superior stability in acidic media and its critical role in the reductive amination of aldehydes and ketones during the synthesis of complex active pharmaceutical ingredients (APIs). The market is currently seeing a significant shift towards more rigorous analytical control strategies, such as chromatographic assays, to monitor and mitigate residual free cyanide impurities that can lead to undesired side products in bioconjugation processes for proteins and peptides. Furthermore, while the broader borohydride sector is projected to reach USD 376 million by 2032 with a CAGR of 6.6%, sodium cyanoborohydride maintains a specialised niche for hindered-ketone API synthesis due to its documented high yields and selectivity compared to alternative reducing agents, despite increasing pricing pressures from raw material fluctuations. As globally established Sodium cyanoborohydride supplier with 97% min. purity %. We ensure dependable supply, consistent quality, and complete regulatory documentation, including Sodium cyanoborohydride CoA and Sodium cyanoborohydride TDS across all grades. Beyond supply, we support partners through the entire product lifecycle from route scouting, process and formulation development, and analytical method development to scale-up, process optimisation, and pilot-to-commercial manufacturing. Our teams also assist with GMP-compliant quality assurance, regulatory documentation, and global supply chain and logistics coordination.